Bellevue, WA (canadaTECH.INFO) – June 9, 2008 - Oncothyreon Inc. (TSX: ONY; Nasdaq: ONTY) has appointed Daniel K. Spiegelman and Stephen K. Burley, M.D., D.Phil. to its board of directors for three-year terms. S. Robert Blair has retired from the board of directors.

Spiegelman is Senior Vice President and Chief Financial Officer at CV Therapeutics in Palo Alto, California. He will assume the chairmanship of the audit committee at Oncothyreon on July 1, 2008. Dr. Burley is Chief Scientific Officer and Senior Vice President at SGX Pharmaceuticals, Inc., and Adjunct Professor at both the Rockefeller University and the University of California in San Diego.

Oncothyreon, formerly Biomira Inc. of Edmonton, Alberta, is a biotechnology company specializing in the development of innovative therapeutic products for the treatment of cancer. Oncothyreon's goal is to develop and commercialize novel synthetic vaccines and targeted small molecules that have the potential to improve the lives and outcomes of cancer patients.